Aurum Biosciences

Aurum Biosciences Ltd is a biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, cancer, epilepsy, and dementia. Aurum is currently taking a stroke management product (“GOLD”) through preclinical development and into clinical studies of efficacy and safety.

Aurum develops novel pharmaceuticals for use in several different clinical indications of high unmet medical need. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.

Media Gallery



Aurum raises £670k as part of a new round of equity funding


ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging


Aurum Biosciences Has Second Patent Granted in the EU


Aurum Publishes Paper on ABL-101 Technology


Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients


Aurum Biosciences is delighted to announce that Dr Jo Bhattacharaya has joined the Scientific Advisory Board


Aurum Biosciences is delighted to announce that Elaine Ferguson has joined us as our Chief Financial Officer


Aurum Invited to London Stock Exchange by Minister for Life Sciences


Members of the Scottish Parliament Welcome Investment in Aurum Biosciences Ltd, a Spin Out Company of NHSGGC and the University of Glasgow


Aurum Biosciences raises £3M ($4.5M) from investors in UK and USA and signs strategic US partnership


Aurum Biosciences has Patent Granted in the United States

  • Graham Watson, Executive Chair, SHIL

    “SHIL has been working with Aurum Biosciences for over five years following the successful spin-out from NHS Greater Glasgow and Clyde and the University of Glasgow. Significant progress has been made in advancing the diagnosis and treatment of stroke with promising results evident in pre-clinical trials. This is vital work; in Scotland alone stroke remains the third biggest killer and the leading cause of disability. This new investment from SHIL and other investors, combined with ambitious development plans, will support the team to extend their work in stroke, and other conditions; with the ultimate aim of saving and improving lives."

    Graham Watson, Executive Chair, SHIL